Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
Immune checkpoint inhibitors (ICIs) have shown great promise as immunotherapy for restoring T cell function and reactivating anti-tumor immunity.The US Food and Drug Administration (FDA) approved the first immune Ceiling Light checkpoint inhibitor, ipilimumab, in 2011 for advanced melanoma patients, leading to significant improvements in survival r